<DOC>
	<DOCNO>NCT01292187</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy oral calcitonin ( rsCT ) tablets prevention bone loss postmenopausal woman low bone mineral density increase risk fracture . The secondary purpose study determine food effect compare efficacy safety oral calcitonin tablet administer dinner bedtime .</brief_summary>
	<brief_title>A Study Oral Recombinant Salmon Calcitonin ( rsCT ) Prevent Postmenopausal Osteoporosis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled Phase 2 study conduct entirely US . The subject post-menopausal woman whose 10-year risk major osteoporotic fracture assess use World Health Organization ( WHO ) Fracture Risk Assessment Tool ( FRAX® ) algorithm within first 3 visit . Eligible , consent subject enrol begin 2- week single-blind placebo run-in phase determine tolerability . After run-in phase , continue subject randomize 2:1 ratio receive oral calcitonin placebo . All subject take 600 mg calcium citrate 1000 IU vitamin D daily breakfast begin run-in phase . The duration treatment include run-in phase 54 week . Bone mineral density ( BMD ) C-terminal telopeptide type 1 collagen ( CTx-1 ) determine Baseline Weeks 28 54 randomization . The % change baseline lumbar spine BMD calculate compare : active placebo . The change baseline plasma CTx-1 also calculate compare likewise . To confirm effect meal time product , subject arm randomize take active placebo empty stomach bedtime meal dinnertime .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Female least 45 year age . Must undergone onset spontaneous surgical menopause 5 year prior entry . Spontaneous menopause define 12 month spontaneous amenorrhea . Surgical menopause define ≥ 6 week postsurgical bilateral oophorectomy without hysterectomy . Serum folliclestimulating hormone ( FSH ) level must ≥ 30 mIU/mL . A body mass index ( BMI ) great 35 ( BMI =weight [ kg ] /height [ ] 2 ) . Bone mineral density ( BMD ) Tscore 1.0 2.5 total hip , femoral neck , trochanter , lumbar spine . Additional risk factor 10 year risk major osteoporotic fracture hip fracture risk least great 65yearold woman race BMI 25 kg/m2 determine FRAX algorithm . No clinically significant abnormal finding medical history physical exam would preclude participation investigator 's opinion . No clinically significant abnormal laboratory value screen assessment . Subjects must give write informed consent read Subject Information Consent Form opportunity discus study investigator . History osteoporotic fracture , defined fracture wrist , hip , humerus occur fall stand height less . BMD TScore site ≤ 2.5 . Current treatment ( within 3 month prior randomization ) hormone replacement therapy . History metabolic bone disease , include osteogenesis imperfecta , osteomalacia , Paget 's disease . Vitamin D insufficiency define 25 hydroxyvitamin D level &lt; 20 ng/mL ( 50 nmol/L ) . Prior use calcitonin , ever . Prior use bisphosphonate , ever . Prior use denosumab , fluoride , strontium , ever . Prior use parathyroid hormone analog , ever . Any condition disease may interfere ability dual energy xray absorptiometry ( DXA ) scan evaluate DXA scan , example , severe osteoarthritis spine , spinal fusion , pedicle screw , history vertebroplasty , degenerative disease result insufficient number evaluable lumbar vertebra , bilateral hip replacement . Use anabolic steroid androgen within 6 month precede randomization . Use vitamin D metabolite analog , ( e.g. , calcitriol ) within 3 month precede randomization ) . Note : Vitamin D supplementation exclusionary . Use estrogen estrogenrelated drug ( include selective estrogen receptor molecule ) , example , tamoxifen , tibolone , raloxifene within 3 month precede randomization . Chronic systemic treatment glucocorticoid . Clinically relevant abnormal history , physical finding , laboratory value prestudy screen assessment could interfere objective study safety subject . Presence acute chronic illness history chronic illness , judgment investigator , make participation study medically inappropriate . Known acquire immune deficiency syndrome ( AIDS ) human immunodeficiency virus ( HIV ) seropositivity . Uncontrolled hypertension , significant gastrointestinal abnormality , uncontrolled diabetes mellitus , significant coronary heart disease , psychotic mental illness , chronic allergic rhinitis , asthma , uncorrected endocrine dysfunction , significantly impaired hepatic , respiratory , renal function . Participation clinical study within previous month . History drug alcohol abuse , intake 30 unit alcohol weekly . Possibility subject cooperate requirement protocol . Known sensitivity sCT . Shift workersindividuals work overnight hour .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis , Postmenopausal</keyword>
	<keyword>Bone Diseases , Metabolic</keyword>
	<keyword>Bone Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Salmon calcitonin</keyword>
	<keyword>Calcitonin</keyword>
</DOC>